Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xeris Biopharma Holdings (XERS) Cash from Operations: 2020-2025

Historic Cash from Operations for Xeris Biopharma Holdings (XERS) over the last 5 years, with Sep 2025 value amounting to $18.4 million.

  • Xeris Biopharma Holdings' Cash from Operations rose 321.94% to $18.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $10.6 million, marking a year-over-year increase of 133.53%. This contributed to the annual value of -$37.0 million for FY2024, which is 21.36% up from last year.
  • Latest data reveals that Xeris Biopharma Holdings reported Cash from Operations of $18.4 million as of Q3 2025, which was up 10,027.47% from $182,000 recorded in Q2 2025.
  • Xeris Biopharma Holdings' 5-year Cash from Operations high stood at $18.4 million for Q3 2025, and its period low was -$48.4 million during Q1 2022.
  • For the 3-year period, Xeris Biopharma Holdings' Cash from Operations averaged around -$6.9 million, with its median value being -$10.0 million (2025).
  • As far as peak fluctuations go, Xeris Biopharma Holdings' Cash from Operations crashed by 166.32% in 2021, and later spiked by 321.94% in 2025.
  • Over the past 5 years, Xeris Biopharma Holdings' Cash from Operations (Quarterly) stood at -$28.9 million in 2021, then soared by 44.31% to -$16.1 million in 2022, then surged by 146.35% to $7.5 million in 2023, then crashed by 73.56% to $2.0 million in 2024, then spiked by 321.94% to $18.4 million in 2025.
  • Its last three reported values are $18.4 million in Q3 2025, $182,000 for Q2 2025, and -$10.0 million during Q1 2025.